286 related articles for article (PubMed ID: 10811458)
41. Omega-3 and omega-6 polyunsaturated fatty acids enhance arsenic trioxide efficacy in arsenic trioxide-resistant leukemic and solid tumor cells.
Wirtitsch M; Roth E; Bachleitner-Hofmann T; Wessner B; Sturlan S
Oncol Res; 2009; 18(2-3):83-94. PubMed ID: 20066898
[TBL] [Abstract][Full Text] [Related]
42. The potential of arsenic trioxide in the treatment of malignant disease: past, present, and future.
Evens AM; Tallman MS; Gartenhaus RB
Leuk Res; 2004 Sep; 28(9):891-900. PubMed ID: 15234563
[TBL] [Abstract][Full Text] [Related]
43. Therapeutic effect of arsenic trioxide (As2O3) on cervical cancer in vitro and in vivo through apoptosis induction.
Yu J; Qian H; Li Y; Wang Y; Zhang X; Liang X; Fu M; Lin C
Cancer Biol Ther; 2007 Apr; 6(4):580-6. PubMed ID: 17374990
[TBL] [Abstract][Full Text] [Related]
44. Chloroquine aggravates the arsenic trioxide (As2O3)-induced apoptosis of acute promyelocytic leukemia NB4 cells via inhibiting lysosomal degradation in vitro.
Liu DM; Zhang XD; Yang L
Eur Rev Med Pharmacol Sci; 2018 Oct; 22(19):6412-6421. PubMed ID: 30338810
[TBL] [Abstract][Full Text] [Related]
45. Down-regulation of wt1 expression in leukemia cell lines as part of apoptotic effect in arsenic treatment using two compounds.
Glienke W; Chow KU; Bauer N; Bergmann L
Leuk Lymphoma; 2006 Aug; 47(8):1629-38. PubMed ID: 16966277
[TBL] [Abstract][Full Text] [Related]
46. Arsenic trioxide induces apoptosis in HTLV-I infected T-cell lines and fresh adult T-cell leukemia cells through CD95 or tumor necrosis factor alpha receptor independent caspase activation.
Ishitsuka K; Ikeda R; Utsunomiya A; Uozumi K; Hanada S; Suzuki S; Takeuchi S; Takatsuka Y; Takeshita T; Ohno N; Arima T
Leuk Lymphoma; 2002 May; 43(5):1107-14. PubMed ID: 12148893
[TBL] [Abstract][Full Text] [Related]
47. As2O3 enhances the anion transport activity of band 3 and the action is related with the C-terminal 16 residues of the protein.
Fu GH; Wang Y; Xi YH; Guo ZW; Liu XB; Bai SZ; Yang BF; Chen GQ
J Drug Target; 2005 May; 13(4):235-43. PubMed ID: 16051535
[TBL] [Abstract][Full Text] [Related]
48. The use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia.
Zhang P
J Biol Regul Homeost Agents; 1999; 13(4):195-200. PubMed ID: 10703942
[TBL] [Abstract][Full Text] [Related]
49. [In vitro study on arsenic trioxide-induced apoptosis of retinoic acid resistant acute promyelocytic leukemia cell line(MR-2)].
Cai X; Jia P; Shi X
Zhonghua Xue Ye Xue Za Zhi; 1998 Jul; 19(7):339-41. PubMed ID: 11189513
[TBL] [Abstract][Full Text] [Related]
50. Arsenic enhances the activation of Stat1 by interferon gamma leading to synergistic expression of IRF-1.
Chelbi-alix MK; Bobé P; Benoit G; Canova A; Pine R
Oncogene; 2003 Dec; 22(57):9121-30. PubMed ID: 14668793
[TBL] [Abstract][Full Text] [Related]
51. Arsenic trioxide mediates intrinsic and extrinsic pathways of apoptosis and cell cycle arrest in acute megakaryocytic leukemia.
Lam HK; Li K; Chik KW; Yang M; Liu VC; Li CK; Fok TF; Ng PC; Shing MM; Chuen CK; Yuen PM
Int J Oncol; 2005 Aug; 27(2):537-45. PubMed ID: 16010437
[TBL] [Abstract][Full Text] [Related]
52. [In vitro study on arsenic trioxide-inducing apoptosis in primary acute promyelocytic leukemie cells].
Tang W; Chen G; Shen Z; Chen L; Shi X; Jia P; Shi G; Ni J; Chen S; Wang Z
Zhonghua Xue Ye Xue Za Zhi; 1997 Dec; 18(12):623-6. PubMed ID: 15625759
[TBL] [Abstract][Full Text] [Related]
53. Pathologic, cytogenetic and molecular assessment of acute promyelocytic leukemia patients treated with arsenic trioxide (As2O3).
Zhang T; Westervelt P; Hess JL
Mod Pathol; 2000 Sep; 13(9):954-61. PubMed ID: 11007035
[TBL] [Abstract][Full Text] [Related]
54. Successful treatment of all-trans retinoic acid resistant and chemotherapy naïve acute promyelocytic patients with arsenic trioxide--two case reports.
Lin CP; Huang MJ; Chang IY; Lin WY
Leuk Lymphoma; 2000 Jun; 38(1-2):191-4. PubMed ID: 10811462
[TBL] [Abstract][Full Text] [Related]
55. Arsenic-induced apoptosis in malignant cells in vitro.
Akao Y; Yamada H; Nakagawa Y
Leuk Lymphoma; 2000 Mar; 37(1-2):53-63. PubMed ID: 10721769
[TBL] [Abstract][Full Text] [Related]
56. [The impact of arsenic trioxide or all-trans retinoic acid treatment on coagulopathy in acute promyelocytic leukemia].
Zhang X; Zhou H; Song S; Qiao Z; Yang L; Hu Y
Zhonghua Nei Ke Za Zhi; 2001 Dec; 40(12):829-33. PubMed ID: 16206674
[TBL] [Abstract][Full Text] [Related]
57. The optimal dose of arsenic trioxide induced opposite efficacy in autophagy between K562 cells and their initiating cells to eradicate human myelogenous leukemia.
Guo Z; Meng M; Geng S; Du Z; Zheng Y; Yao J; Li Z; Han G; Lin H; Du G
J Ethnopharmacol; 2017 Jan; 196():29-38. PubMed ID: 27965050
[TBL] [Abstract][Full Text] [Related]
58. Telomere attrition and chromosome instability via downregulation of TRF2 contributes to arsenic trioxide-induced apoptosis of human T-Cell leukemia cell line molt-4 cells.
Jiao Y; Zhang W; Liu J; Ni W; Xu W; Jin J; Qian W
Cancer Biol Ther; 2007 Aug; 6(8):1186-92. PubMed ID: 17643074
[TBL] [Abstract][Full Text] [Related]
59. Arsenic trioxide as first-line treatment for acute promyelocytic leukemia.
Leu L; Mohassel L
Am J Health Syst Pharm; 2009 Nov; 66(21):1913-8. PubMed ID: 19850784
[TBL] [Abstract][Full Text] [Related]
60. Essential role of cell cycle regulatory genes p21 and p27 expression in inhibition of breast cancer cells by arsenic trioxide.
Wang X; Gao P; Long M; Lin F; Wei JX; Ren JH; Yan L; He T; Han Y; Zhang HZ
Med Oncol; 2011 Dec; 28(4):1225-54. PubMed ID: 20458559
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
